STTK

Over the past six months, Shattuck Labs' stock has seen a significant price increase of 184.0% over the past 12 months, with a 52-week range between $1.70 and $8.33. Key clinical trial announcements include a Phase 2 clinical trial of SL-325 in Hidradenitis Suppurativa and a new Senior Vice President of Clinical Development appointment in October 2026. In August 2026, positive Phase 1 clinical trial results for SL-325 were reported, demonstrating a favorable safety profile and durable DR3 blockade, with a Phase 2b clinical trial in Crohn's disease expected to initiate in Q3 2026. The company also reported Q4 and full-year 2025 financial results and business highlights in March 2026. Shattuck Labs participated in investor conferences in September and March 2026 and reported its Q2 2026 financial results on August 11, 2026, along with Q1 2026 earnings. Analysts have a consensus 'Buy' rating with an average price target of $13.33 as of October 5, 2026, with some analysts adjusting their price objectives or ratings. T. Rowe Price Investment Management reported a 15.3% stake in Shattuck Labs on August 14, 2026.